KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EPS (Weighted Average and Diluted) (2020 - 2025)

Acadia Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 9 years, most recently at $1.61 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $1.61 for Q4 2025, up 87.21% from a year ago — trailing twelve months through Dec 2025 was $2.3 (up 69.12% YoY), and the annual figure for FY2025 was $2.3, up 69.12%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $1.61 at Acadia Pharmaceuticals, up from $0.42 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for ACAD hit a ceiling of $1.61 in Q4 2025 and a floor of -$0.7 in Q1 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.04 (2021), compared with a mean of $0.04.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 135.29% in 2023 and later soared 1900.0% in 2024.
  • Acadia Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.27 in 2021, then rose by 3.7% to -$0.26 in 2022, then soared by 207.69% to $0.28 in 2023, then skyrocketed by 207.14% to $0.86 in 2024, then surged by 87.21% to $1.61 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $1.61 (Q4 2025), $0.42 (Q3 2025), and $0.16 (Q2 2025) per Business Quant data.